| Study | Participants, no. (% male) | Funding | Design | Centre(s) | Timing of troponin measurement | Outcome, no. (%) | Follow-up period |
|---|---|---|---|---|---|---|---|
| Troponin T | |||||||
| Reichlin et al. 2009 (9) | 718 (66) | Swiss Heart Foundation, University Hospital, Basel, Abbott, Roche, Siemens | Prospective | Multicentre: Switzerland, Italy and Spain | At presentation and 6–9 h later | MI 123 (17) | 60 d |
| Christ et al. 2010 (10) | 2340 (64) | Roche Diagnostics | Retrospective | Single centre: Germany | At presentation and about 6 h later | MI 20 (15) | 2 wk |
| Aldous et al. 2011 (11) | 332 (60) | National Heart Foundation of New Zealand, Christchurch Hospital, Roche Diagnostics | Prospective | Single centre: New Zealand | At presentation and 6–24 h later | MI 110 (33) | Not reported |
| Body et al. 2011 (12) | 703 (61) | Manchester NHS Foundation Trust, Roche Diagnostics | Prospective | Single centre: United Kingdom | At presentation and (at least) 12 h after onset of symptoms | MI 130 (18) | 6 mo |
| Freund et al. 2011 (13) | 317 (65) | Université Pierre et Marie Curie-Paris 6, Roche Diagnostics | Prospective | 3 centres: France | At presentation and 3–9 h later (if clinically indicated) | MI 45 (14) | 30 d |
| Melki et al. 2011 (14) | 233 (67) | Stockholm County Council and Karolinska Institute, Swedish Heart and Lung Foundation, National Board of Health and Welfare, Roche Diagnostics | Prospective | Single centre: Sweden | At presentation and 9–12 h later | MI 114 (48) | Discharge from hospital |
| Reiter et al. 2011 (15) | 1098 (67)* | Swiss Heart Foundation, University Hospital, Basel, Abbott, Roche, Siemens | Prospective | Multicentre: Switzerland, Italy and Spain | At presentation and 6–9 h later | MI 159 (14) | 90 d |
| Weber et al. 2011 (16) | 2506 (66) | Kerckhoff-Stiftung Foundation, Sanofi Aventis, Roche Diagnostics | Retrospective analysis of data from 2 acute coronary syndrome registries | Multicentre: Germany and Argentina | At presentation | MI 1082 (43) | 6 mo |
| Aldous et al. 2012 (17) | 939 (59) | National Heart Foundation of New Zealand, Health Research Council of New Zealand, Roche Diagnostics | Prospective | Multicentre: 9 countries in the Asia-Pacific region | At presentation, 2 h and 6–12 h later | MI 205 (21) | 1 yr |
| Troponin I | |||||||
| Reichlin et al. 2009 (9) | 718 (66) | Swiss Heart Foundation, University Hospital, Basel, Abbott, Roche, Siemens | Prospective | Multicentre: Switzerland, Italy and Spain | At presentation and 6–9 h later | MI 123 (17) | 60 d |
| Keller et al. 2009 (24) | 1818 (66) | Not available | Prospective | Multicentre: Germany | At presentation and 3–6 h later | MI 413 (23) | 30 d |
| Bhardwaj et al. 2011 (23) | 318 (54) | Inverness Medical Innovations | Prospective | Multicentre: United States | At presentation and repeated if clinically indicated | ACS 62 (20) | 30 d |
Note: ACS = acute coronary syndrome, MI = myocardial infarction. *Older population (≥ 70 yr).